Moditen Depo (Fluphenazine Decanoate)

Fluphenazine decanoate, the active ingredient in Moditen Depo, is a phenothiazine presented as a depot injection for intravenous use. It treats schizophrenia and other psychotic disorders in adult patients.

GNH USA supplies Moditen Depo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fluphenazine decanoate is a typical antipsychotic used in the management of dopamine‑mediated psychotic disorders.

Schizophrenia: Reduces positive symptoms such as hallucinations and delusions, improving overall functioning. Acute psychotic episodes: Provides rapid symptom control when administered as a depot formulation. Maintenance therapy for chronic psychosis: Sustains therapeutic plasma levels over weeks, supporting adherence and relapse prevention.

Fluphenazine decanoate may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Extrapyramidal symptoms: Tremor, rigidity, bradykinesia, or akathisia. - Sedation: Drowsiness or reduced alertness. - Anticholinergic effects: Dry mouth, constipation, blurred vision. - Weight gain: Increased appetite leading to modest weight increase.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: Life‑threatening hyperthermia, severe muscle rigidity, autonomic instability. - Tardive dyskinesia: Persistent involuntary movements that may be irreversible. - Cardiovascular events: Orthostatic hypotension, arrhythmias, or QT‑interval prolongation.

When prescribing fluphenazine decanoate, clinicians should observe several safety measures.

Monitor for extrapyramidal symptoms: Assess motor function regularly. Screen for metabolic changes: Check weight, glucose, and lipid levels periodically. Assess cardiovascular status: Observe blood pressure and heart rate, especially after the first dose. Avoid use in patients with known hypersensitivity to phenothiazines: Discontinue if a reaction occurs. Pregnancy and lactation: Use only if benefits outweigh risks; data are limited. Store at ambient temperature: Keep below 25°C, protect from moisture and light, retain in original packaging.

Fluphenazine decanoate interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluvoxamine): May increase fluphenazine levels, raising toxicity risk. - Anticholinergic drugs (e.g., benztropine): May exacerbate anticholinergic side effects. - QT‑prolonging agents (e.g., haloperidol): Combined use can increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, alcohol): Additive sedation; monitor level of consciousness. - Dopamine agonists (e.g., levodopa): May reduce antipsychotic efficacy; adjust therapy as needed. - Lithium: May increase risk of neuroleptic malignant syndrome; monitor closely.